Category Archives: Healthcare

04.03.14

July 14-18 – Emerging Issues in Food and Drug Law (O'Neill Institute Summer Program with Confirmed Speakers)

By | Leave a Comment

Please join the O’Neill Institute for National and Global Health Law at Georgetown University for a one-week intensive summer institute exploring the domestic and international legal, regulatory, and policy framework shaping the safety and availability of foods and medicines worldwide. The program will cover U.S. domestic law including recent laws and regulations; international regulatory harmonization […]

Posted in FDA, Global Health, Health reform, Healthcare, Tobacco, Trade, uncategorized ; Tagged: , , , , .

04.02.14

Five Things About the Affordable Care Act Post Open Enrollment

By | Leave a Comment

This post was co-authored by Michael Templeman, Director, New Initiatives at the O’Neill Institute for National and Global Health Law. The first open enrollment period for the Affordable Care Act (ACA), or “Obamacare” officially closed on March 31.  Here are five things to know about the ACA post-open enrollment. 1. Number of Enrollees Has Exceeded […]

Posted in Health reform, Healthcare, uncategorized ; Tagged: , , , .

03.13.14

Is obesity the ticket to fighting antibiotic resistance?

By | Leave a Comment

Research points to the possibility that taking antibiotics could lead to weight gain. Could this reality be the necessary catalyst to change the way we use antibiotics in general?Antibiotic overuse is a public health crisis. For decades, scientists have supported changing antibiotic prescribing practices in response to the alarming consequences of their overuse – most […]

Posted in FDA, Global Health, Healthcare, uncategorized ; Tagged: , .

02.12.14

Do prescription drugs need a message?

By | Leave a Comment

The recent controversy surrounding a relatively new blood thinner called Pradaxa (dabigatran) centers not on the drug itself, but on the safety of the drug’s message. Brought to market as a superior product to the long-standing market leader, Coumadin (warfarin), Pradaxa is touted for its ability to treat atrial fibrillation without the inconvenience of frequent […]

Posted in FDA, Healthcare ;

02.07.14

CVS’s Bold Move: Goodbye Tobacco, Hello Health Care

By | Leave a Comment

 This week, the second-largest drugstore chain CVS Caremark Corp. (CVS) announced that it will stop selling tobacco products in its 7,600 pharmacies starting on October 1. The medical and tobacco control advocacy organizations applaud the decision, as it contributes to combatting tobacco consumption in the U.S. and exerts pressure on competitors to do the same. […]

Posted in Health reform, Healthcare, Tobacco ; Tagged: , , , , , , , , , .

01.13.14

Four things we should probably stop doing in the name of public health in 2014

By | Leave a Comment

Within public health, we have many victories to claim. Vaccinations – for example – have been and remain unmitigated successes. Yet, there are many public health interventions that have been instituted and promoted by public health advocates, medical doctors, and various pharmaceutical or medical device companies that have proven to be ineffective at improving health […]

Posted in Global Health, Healthcare ;

11.27.13

Retail Clinic: Friend or Foe?

By | Leave a Comment

After not being able to get his son to the doctor for a strep throat test, Rick Krieger established the first retail clinic at a local grocery chain in 2000. The idea was to address issues of access to health care and allow patients to obtain care and treatment for minor conditions “in a quick, […]

Posted in Healthcare ; Tagged: , , , , , , , , , , , , , , , , , , , , .

07.22.13

Will FDA Turn the Tide on Industry-wide Medical Product Development?

By | Leave a Comment

The advent of big data has forced a sea change throughout the scientific research enterprise, shaking the industry’s fundamental attitude towards the data themselves. Data is now understood as the currency of research. Consequently, industry is warming to the new reality that legal norms once considered to drive business – confidential commercial information, trade secrets […]

Posted in FDA, Health reform, Healthcare, Updates ; Tagged: , , , .

06.21.13

The End of “Pay-for-Delay”? By Opening Collusive Pharmaceutical Settlements to Antitrust Scrutiny, FTC v. Actavis Promises to Make Medicines More Affordable

By | Leave a Comment

  In a decision that could save U.S. consumers and taxpayers billions of dollars a year, the Supreme Court ruled Monday that “pay-for-delay,” also known as “reverse payment” settlements, between name-brand and generics pharmaceutical companies are subject to antitrust laws. The seeds of the controversy were planted in 1984 with the passage of the Hatch-Waxman […]

Posted in Healthcare, uncategorized ; Tagged: , , , , .

04.30.13

The Power of Sharing: Rethinking the Future of Intellectual Property and Biomedical Research

By | Leave a Comment

Recently, the U.S. Supreme Court heard oral arguments in Association for Molecular Pathology v. Myriad Genetics, Case No. 11-725, on the eligibility of patenting the BRCA1 and BRCA2 genes, which identify hereditary breast and ovarian cancers. The Court granted certiorari to hear this case after a split developed among the United States circuit court of […]

Posted in FDA, Healthcare ;

Stay Informed

Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute

Or sign up for our RSS Feed

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.